1. < Home

Osimertinib

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ,[...]

By sjmartinez • August 22, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial

John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ,[...]

By sjmartinez • May 28, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib

Smith CP, Xiang M, Yoon SM, Lee A, Ruan D, Goldman JW, Cummings AL, Lisberg A, Garon EB, Moghanaki D. Brief Report: Severe Pneumonitis After[...]

By sjmartinez • March 17, 2023